普萘洛尔治疗眼眶婴幼儿血管瘤。
Propranolol for the treatment of orbital infantile hemangiomas.
机构信息
Department of Ophthalmology, University of South Florida College of Medicine, Tampa, Florida, USA.
出版信息
Ophthalmic Plast Reconstr Surg. 2011 May-Jun;27(3):190-4. doi: 10.1097/IOP.0b013e318201d344.
PURPOSE
To evaluate the treatment of orbital infantile hemangiomas with systemic (oral) propranolol.
METHODS
This study was a retrospective observational case series of 5 infants who were diagnosed with orbital infantile hemangiomas between March and July of 2009.
RESULTS
The average age at presentation was 3.1 months (3 weeks to 9 months). The patients received oral propranolol, with dosage varying among study centers. The patients were treated for an average of 7.1 months. Treatment of 5 infantile hemangioma patients with oral propranolol produced a significant reduction in the size of the hemangioma in 4 (80%) of the patients and a minimal improvement in one patient. No patient had significant adverse events during the treatment period.
CONCLUSION
Oral propranolol may be an effective treatment for orbital infantile hemangiomas.
目的
评估系统（口服）普萘洛尔治疗眼眶婴儿血管瘤的效果。
方法
本研究为回顾性观察性病例系列研究，纳入 2009 年 3 月至 7 月期间诊断为眼眶婴儿血管瘤的 5 例婴儿。
结果
平均就诊年龄为 3.1 个月（3 周到 9 个月）。患者接受口服普萘洛尔治疗，各研究中心剂量不同。患者平均治疗 7.1 个月。5 例婴儿血管瘤患者接受口服普萘洛尔治疗后，4 例（80%）患者的血管瘤大小明显缩小，1 例患者有轻微改善。治疗期间无患者发生明显不良反应。
结论
口服普萘洛尔可能是治疗眼眶婴儿血管瘤的有效方法。
Zotero 插件